Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Based on the typical UK regulatory pathway, the most realistic timeline is: Late 2026 / early 2027: Eli Lilly expected to submit regulatory filings to the FDA and MHRA following completion of the remaining TRIUMPH Phase 3 readouts Late 2027 to mid-2028: Possible MHRA marketing authorisation, allowing private UK prescribing 2028 to 2029 onwards: Possible NHS availability following a NICE technology appraisal and NHS commissioning decisions Timelines may differ across the four UK nations, as Scotland, Wales, and Northern Ireland assess medicines separately through the Scottish Medicines Consortium (SMC), All Wales Medicines Strategy Group (AWMSG), and the Department of Health Northern Ireland respectively
Ozempic is a prescription medication containing semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed to improve blood sugar control in adults with type 2 diabetes
The phase 2 data shows variable results
Two edge cases deserve explicit framing
US$ 20.10
US$ 20.09
US$ 25.10
